Study on the Antiviral Efficacy and Safety of Nucleoside (Nucleotide) Analogues in Breast Cancer Patients with Chronic HBV Infection Undergoing Chemotherapy

Start Date01 Jun 2025

Sponsor / Collaborator

Fujian Medical University Union Hospital

[+1]

NCT06990438

/ Not yet recruitingNot ApplicableIIT

Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B

This study aims to evaluate the effect of long-term use of Tenofovir Disoproxil Fumarate (TDF) on bone density in patients with chronic hepatitis B virus (HBV) infection. Tenofovir is a widely used antiviral medication for the treatment of HBV. While it is generally well tolerated, some studies have reported potential adverse effects on bone mineral density, particularly with long-term use.
The objective of this research is to assess whether extended TDF therapy is associated with reduced bone density or increased risk of osteopenia or osteoporosis in adult patients with chronic HBV infection. The study will involve clinical evaluation and radiological assessment of bone health using dual-energy X-ray absorptiometry (DEXA) scans, as well as relevant biochemical markers.
This investigation will provide important data on the long-term safety profile of Tenofovir in relation to bone health and help guide future clinical decisions for the management of chronic hepatitis B.

Start Date22 May 2025

Sponsor / Collaborator

Assiut University

NCT06896630

/ Not yet recruitingNot ApplicableIIT

Effect of Long-Term Use of Tenofovir (TDF) on Renal Function in Patients With Chronic Hepatitis B

Effect of Long-Term Use of Tenofovir (TDF) on Renal Function in Patients with Chronic Hepatitis B Over a Five-Year Period

Start Date10 Apr 2025

Sponsor / Collaborator

Assiut University

100 Clinical Results associated with Tenofovir Disoproxil Fumarate

100 Translational Medicine associated with Tenofovir Disoproxil Fumarate

100 Patents (Medical) associated with Tenofovir Disoproxil Fumarate

6,218

Literatures (Medical) associated with Tenofovir Disoproxil Fumarate

31 Dec 2025·HIV Research & Clinical Practice

Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm

Article

BACKGROUND:

Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of Emtricitabine/Tenofovir (TDF/FTC) in active-controlled pre-exposure prophylaxis (PrEP) trials has been suggested. However, it has not yet been widely applied. In this article, we evaluate adherence to TDF/FTC in the PrEPVacc trial (NCT04066881) and consider how such adherence data could be used to estimate the effectiveness of TDF/FTC and subsequently, HIV incidence in a counterfactual placebo arm in a predominantly female population.

METHODS:

From December 2020 to March 2023 participants were recruited into the trial which included a comparison of Emtricitabine/Tenofovir Alafenamide (TAF/FTC) to TDF/FTC as PrEP over 26 weeks of follow-up, in Uganda, Tanzania, and South Africa. PrEP adherence was assessed in various ways.

RESULTS:

Of 697 participants dispensed TDF/FTC, 87% were female, 54% were ≥ 25 years, and 59% were sex workers. In a random sample (41%) assessed at visit 6 (week 8), 76% had detectable TFV-DP levels, with 22% reaching levels consistent with ≥2 pills/week. Males, Verulam and Mbeya participants, those ≥ 25 years, not single, subsistence fisheries workers, and those who had any STI at baseline were more likely to have higher adherence. Of those assessed at visit 6, 29% were identified as white coat dosing. Estimated (crude) HIV incidence risk reduction ranged from 10% to 65%.

CONCLUSIONS:

TDF/FTC adherence in the PrEPVacc trial was low, with considerable levels of white coat dosing. Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of TDF/FTC is a promising approach, however, the approach requires further elaboration and evaluation.

31 Dec 2025·HIV Research & Clinical Practice

A combined prospective and retrospective comparative study evaluating renal outcomes after switching from TDF + FTC + EFV to TDF/3TC/DTG (TLD) vs. DTG + 3TC in virologically suppressed Thai people with HIV

Article

Author: Putcharoen, Opass ; Kanogtorn, Sathaporn ; Burimat, Phattarapon ; Patamatamkul, Samadhi

BACKGROUND:

TDF/3TC/DTG (TLD) has been adopted as the first-line therapy for all people with HIV according to the WHO 2019 and Thai HIV guidelines. As a result, people with HIV in Thailand on TDF/FTC/EFV are switched to TLD. However, increasing data demonstrate the efficacy and renal safety of the TDF-sparing dual therapy with DTG + 3TC compared with TDF-based combination ART (cART) as a switching therapy. A direct comparison of estimated glomerular filtration rates (eGFR) among people with HIV treated with TDF-based regimens who switch to TLD vs. DTG + 3TC is yet to be made.

METHODS:

We enrolled virologically suppressed people with HIV aged ≥18 years currently on TDF + FTC + EFV to either switch to TLD or DTG + 3TC at two tertiary care hospitals. The switching regimen was chosen at the physicians' discretion. The primary outcome was the change in eGFR, calculated by creatinine at 24 weeks. Secondary outcomes included changes in LDL, body weight, and BMI at 24 weeks.

RESULTS:

Among 53 recruited participants, 28 and 15 completed the second follow-up in the TLD and DTG + 3TC groups, respectively. The mean age was higher in the TLD group compared to the DTG + 3TC group (Table 1). The median time from HIV diagnosis to switching was 8.5 years. The eGFR reduction was significantly greater in the TLD group than in the DTG + 3TC group: -17.24 ± 9.24 vs. -8.4 ± 9.03 mL/min/1.73 m² (p = 0.004). All participants in both groups achieved virological suppression. There was no significant change in CD4 counts between the two groups. Switching to DTG + 3TC was associated with a significantly smaller decline in eGFR post-switch (mean difference: 6.216 mL/min/1.73 m²; 95% CI 0.169-12.263; p = 0.044) compared to those who switched to TLD.

CONCLUSIONS:

There was a significant reduction in eGFR among people with HIV who switched to TLD compared to those switched to DTG + 3TC. Changes in LDL and BMI were comparable between groups. Dual therapy with DTG + 3TC may be a preferred switching option over TLD for individuals with renal safety concerns. Further randomized prospective trials with longer follow-up are warranted to confirm these findings.

01 Dec 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Development of colorimetric immunochromatographic assay based on different morphologies of gold nanoparticles for the detection of triadimefon

Article

Author: Luo, Ruifeng ; Zhu, Zixin ; Dong, Sa ; Feng, Jianguo ; Zhang, Yu ; Shi, Qiuyun ; Wang, Yulong

Triadimefon (TDF) is a highly effective, low toxicity, broad-spectrum triazole fungicide with strong systemic absorption. Excessive residues in tobacco and vegetables can affect human health. Therefore, it is urgent to establish a simple, rapid, and sensitive detection method for residual analysis of TDF in tobacco and vegetables. In this study, colloidal gold nanoparticles (Au NPs), gold nanoflowers (Au NFs), and gold nanorods (Au NRs) were synthesized and combined with anti-TDF monoclonal antibodies (mAb) to prepare probes for immunochromatographic strips (ICS). The lowest visual detection limits (vLODs) of the test strips using AuNPs-mAb, AuNFs-mAb, and AuNRs-mAb as probes were 7.8, 15.6, and 15.6 ng/mL, respectively. The three test strips showed no significant cross reactivity with the four structural analogues of tebuconazole, hexaconazole, myclobutanil, and difenoconazole, indicating that all three test strips have good specificity. To assess the presence of 0 and 62.5 ng/mL of TDF, ten test strips were used, and the results showed perfect accuracy with no false positives or false negatives. In addition, three test strips (same batch) were utilized to detect TDF (0 and 62.5 ng/mL) after storage for three months, and the results were still accurate, indicating that all three kinds of test strips have good repeatability and stability. The addition and recovery tests of TDF were conducted on cucumber and tobacco leaf samples (0, 2.5, 17.5, and 65 μg/kg), and the test results revealed that the strips performed with high accuracy. This study established three colorimetric test strips based on three different morphologies of gold nanoparticles, which possess the benefits of quick processing times, high cost-effectiveness, and minimal technical requirements, making them suitable for rapid on-site qualitative detection of TDF.

185

News (Medical) associated with Tenofovir Disoproxil Fumarate

13 Aug 2025

·pipelinereview.com

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, CA, USA I August 13, 2025 I Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection. “Despite available treatments for chronic HBV infection, better therapies are needed to stem the progression to end-stage liver disease and liver cancer,” said Nezam Afdhal, MD, DSc, Chief of Gastroenterology, Hepatology, and Nutrition at Beth Israel Deaconess Medical Center and Charlotte & Irving Rabb Distinguished Professor of Medicine at Harvard Medical School. “I am pleased that therapies such as Aligos’ ALG-000184 are continuing to progress. The impressive antiviral activity seen in clinical trials to date provides hope for patients in need.” “Dosing the first subjects in our Phase 2 B-SUPREME study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “We are pleased by the engagement of the clinicians and subjects, as they recognize the need for improved treatment regimens for chronic HBV infection. We believe that ALG-000184 has first/best-in-class potential based on the exciting data seen across viral markers of HBV to date. We look forward to continuing to advance ALG-000184 for patients in need of better outcomes.” The Phase 2 B-SUPREME study (NCT06963710) is a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated HBeAg + and HBeAg – adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg + part will be HBV DNA

Phase 2Phase 1Clinical ResultVaccine

13 Aug 2025

·investor.aligos.com

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection. “Despite available treatments for chronic HBV infection, better therapies are needed to stem the progression to end-stage liver disease and liver cancer,” said Nezam Afdhal, MD, DSc, Chief of Gastroenterology, Hepatology, and Nutrition at Beth Israel Deaconess Medical Center and Charlotte & Irving Rabb Distinguished Professor of Medicine at Harvard Medical School. “I am pleased that therapies such as Aligos’ ALG-000184 are continuing to progress. The impressive antiviral activity seen in clinical trials to date provides hope for patients in need.” “Dosing the first subjects in our Phase 2 B-SUPREME study is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “We are pleased by the engagement of the clinicians and subjects, as they recognize the need for improved treatment regimens for chronic HBV infection. We believe that ALG-000184 has first/best-in-class potential based on the exciting data seen across viral markers of HBV to date. We look forward to continuing to advance ALG-000184 for patients in need of better outcomes.” The Phase 2 B-SUPREME study (NCT06963710) is a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated HBeAg+ and HBeAg- adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg+ part will be HBV DNA

Phase 2Phase 1Clinical ResultVaccine

06 Aug 2025

·investor.aligos.com

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2025. “Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway with regulatory approvals across a number of countries, including the US, China, Canada, Taiwan, UK, New Zealand, and Moldova,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “Site activations are in progress, subjects are being screened, and we expect dosing to commence in the coming weeks. This pertinent study is the next step in our journey to potentially deliver better therapies for patients living with HBV infection and create value for our stakeholders. The Phase 1 data showcasing 96 weeks of treatment presented at the EASL meeting suggests that ALG-000184 has the potential to replace standard of care treatment for chronic suppression of HBV infection and may become the backbone of treatments aimed at a functional cure. We remain excited about the potential of ALG-000184 and the entirety of our pipeline, including ALG-055009 which remains in discussions with potential partners.” Recent Business Progress Pipeline Updates ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection The Phase 2 B-SUPREME study (NCT04746183) of ALG-000184 in subjects with chronic HBV infection recently began obtaining regulatory approvals, activating global sites, and screening subjects. Dosing is expected to commence in the coming weeks. The study is designed as a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated HBeAg+ and HBeAg- adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg+ part will be HBV DNA

Clinical ResultPhase 1Phase 2Financial Statement

100 Deals associated with Tenofovir Disoproxil Fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
D01982	-	J05AF07	DB00300

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Virus Diseases	China	Gilead Sciences, Inc.	18 Jun 2008
Hepatitis B	European Union	Gilead Sciences Ireland UC	04 Feb 2002
Hepatitis B	Iceland	Gilead Sciences Ireland UC	04 Feb 2002
Hepatitis B	Liechtenstein	Gilead Sciences Ireland UC	04 Feb 2002
Hepatitis B	Norway	Gilead Sciences Ireland UC	04 Feb 2002
Hepatitis B, Chronic	European Union	Gilead Sciences Ireland UC	04 Feb 2002
Hepatitis B, Chronic	Iceland	Gilead Sciences Ireland UC	04 Feb 2002
Hepatitis B, Chronic	Liechtenstein	Gilead Sciences Ireland UC	04 Feb 2002
Hepatitis B, Chronic	Norway	Gilead Sciences Ireland UC	04 Feb 2002
HIV Infections	United States	Gilead Sciences, Inc.	26 Oct 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	Thailand	Gilead Sciences, Inc.	01 Jan 2013
Lymphoma	Phase 2	United States	GSK Plc	01 Dec 2015
Non-Hodgkin Lymphoma	Phase 2	United States	GSK Plc	01 Dec 2015
End Stage Liver Disease	Phase 2	United States	Gilead Sciences, Inc.	01 Apr 2006
End Stage Liver Disease	Phase 2	Canada	Gilead Sciences, Inc.	01 Apr 2006
End Stage Liver Disease	Phase 2	France	Gilead Sciences, Inc.	01 Apr 2006
End Stage Liver Disease	Phase 2	Germany	Gilead Sciences, Inc.	01 Apr 2006
End Stage Liver Disease	Phase 2	Greece	Gilead Sciences, Inc.	01 Apr 2006
End Stage Liver Disease	Phase 2	Italy	Gilead Sciences, Inc.	01 Apr 2006
End Stage Liver Disease	Phase 2	Poland	Gilead Sciences, Inc.	01 Apr 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04202536 (Pubmed \| Clin Mol Hepatol)	Phase 4	Hepatitis B, Chronic hepatitis B virus (HBV) DNA	153	Besifovir 150 mg	pzwtkzvtow(byrucvjxvg) = ooacuepqsq pmdatoxtff (yegsbthddi )	Positive	01 Jul 2025
				Tenofovir Disoproxil Fumarate 300 mg	pzwtkzvtow(byrucvjxvg) = wrzdlmiaoo pmdatoxtff (yegsbthddi )
NCT03920618 (Pubmed \| Liver Res)	Not Applicable	Acute-On-Chronic Liver Failure	199	Tenofovir alafenamide (TAF)	kenhfxaipv(zwwmqqgazg) = ljheoftfne zyabwtvwmy (xtqfapdaxb ) View more	Positive	01 Dec 2024
				Tenofovir disoproxil fumarate (TDF)	kenhfxaipv(zwwmqqgazg) = qkqcudhmpm zyabwtvwmy (xtqfapdaxb ) View more
NCT03887702 (CTgov)	Phase 3	Hepatitis B \| Malignant Solid Neoplasm	4	Tenofovir Alafenamide+Tenofovir Disoproxil Fumarate+Entecavir (Arm 1 (TAF, TDF, Entecavir: Prophylactic))	xgliknbvkx(lnuheyzyfv) = ivlpgmwlfa cnbcrbxvup (wjajcadgps, llelbwojfq - icrioxviqg) View more	-	20 May 2024
				Tenofovir Alafenamide+Tenofovir Disoproxil Fumarate+Entecavir (Arm 2 (TAF, TDF, Entecavir: Upon Indication))	xgliknbvkx(lnuheyzyfv) = ocfbjkrllm cnbcrbxvup (wjajcadgps, kgmchignjb - ztllfylzzs) View more
NCT03164564 (HPTN 084, CTgov)	Phase 3	HIV Infections	3,224	Placebo for oral TDF/FTC+CAB LA+TDF+FTC+Oral CAB (Arm A: CAB + Placebo TDF/FTC + CAB LA)	lkzawsojsh = hmltuxllgi evatzlwqtb (mcspktkghu, xjpftiaemn - kcaakvmgph) View more	-	28 Mar 2023
				Placebo for CAB LA+TDF+FTC (Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA)	lkzawsojsh = phgxrudehi evatzlwqtb (mcspktkghu, rqznxvoidr - gfngvqobuz) View more
EASL2022	Not Applicable	Hepatitis B, Chronic	48	Tenofovir disoproxil fumarate (TDF)	cuwxvsfehv(hxilmdthpz) = lwsscnfiao mgtqigmeft (bgfcqsikvh )	Positive	25 Jun 2022
NCT02224456 (CTgov)	Phase 4	Hepatitis B, Chronic \| Fibrosis \| Compensated cirrhosis	197	Tenofovir Disoproxil Fumarate	mcdbycyked = uuisfeudms rajddwpiid (otrjpwvsmp, cwtkgfbmhq - gmbnezpzcf) View more	-	14 Feb 2022
NCT02722343 \| NCT02904369 (Pubmed \| J Acquir Immune Defic Syndr)	Phase 1	HIV Infections	22	TDF/FTC oral tablets	jhjvfcrsnk(tpfmzfbopf) = Adverse events (AEs) were more common with oral TDF/FTC use (P < 0.01) tmlqluhewm (uclbgedype )	-	01 Jan 2022
				TFV intravaginal ring
ANRS QUATUOR (IAS2022)	Not Applicable	HIV Infections	42	Intermittent doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF)	vtxqvakheu(rtdorftoag) = osdugkqgkb mbsrstwodp (kmqutczuhz, 77.4 - 97.3) View more	Positive	01 Jan 2022
NCT03258710 (Pubmed \| BMC Gastroenterol) Manual	Phase 4	Hepatitis B, Chronic HBeAg-positive	75	Tenofovir Disoproxil Fumarate	tfcjvqtqwx(cuokpnpmsv) = rvndgyoyws shuhwsbhud (iwqqprzrxo ) View more	Negative	20 Dec 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis